Connect Biopharma Receives Patent for CBP-307

▴ Connect Biopharma Receives Patent for CBP-307
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia

Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules recently announced that, it has received patent grants from the European Patent Office (No. EP3048103B), the United State Patent and Trademark Office (No. US10280158B2) and Japan Patent Office (No. JP6470757B2), and the Australian Patent Office (No. AU2014323822B2) for CBP-307. These issuances broadly expand Connect Biopharma's intellectual property estate for CBP-307 beyond the patent issued by the China National Intellectual Property Administration (No. CN103450171B) in July 2015. The patents cover the composition of matter of the drug candidate and related compounds and have patent terms extending to no earlier than September 2033 for the patent issued in China and to September 2034 for the other patents.

CBP-307 is a proprietary small molecule and orally active S1P1 agonist currently in Phase 2 clinical development in patients with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The molecule was discovered using Connect Biopharma's validated T cell-modulating discovery platform, which radically enhances and speeds identification of best- and first-in-class immune modulators.

In addition to the above-mentioned issued patents, Connect Biopharma has patent and patent applications covering the formulation and other aspects of CBP-307 that are likely to further extend the intellectual property protection of the drug candidate.

"These patent grants provide very strong intellectual property protection for CBP-307 and related compounds in all of our major markets", said Dr. Zheng Wei, Co-founder and CEO of Connect Biopharma. "The successful global patent prosecution of composition of matter of CBP-307 and related compounds validates our innovative capacity and our ability to deliver highly differentiated therapeutics with strong worldwide intellectual property protection. We believe that CBP-307 has tremendous clinical and commercial potential in the treatment of IBD. Our robust patent estate for this molecule creates a significant barrier to competition and strongly positions us to capture a significant portion of the market for IBD therapies, which is projected to reach more than $20 billion globally by 2026 for ulcerative colitis and Crohn's disease."

CBP-307 is a novel second-generation agonist of the sphingosine-1-phosphate 1 receptor (S1P1), a G-protein coupled receptor (GPCR) that plays a central role in regulating T cell movement. Discovered using Connect's proprietary T cell modulation screening platform, CBP-307 is the most potent S1P1 agonist reported and has excellent physiochemical properties. In two completed Phase 1 randomized, double blind, placebo-controlled studies, CBP-307 exhibited an excellent safety profile and potent T cell modulation activity as well as optimal pharmacokinetic and pharmacodynamic profiles, demonstrating best-in-class potential. Two Phase 2 studies of CBP-307 are currently ongoing to evaluate its efficacy and safety in patients with moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease.

Tags : #Connectbiopharma #Intellectualproperty #Inflammatoryboweldiseases #Cbp-307

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Shocking Research Expose the Link Between Traffic Noise and Cardiovascular HealthApril 30, 2024
How Are We Awaken After Anaesthesia: Study Reveals Reveals Brain's Protective MechanismApril 30, 2024
Transformative Parenting Guide "Awakening Parenthood Vol-1" by Rommal Surana Debuts to AcclaimApril 29, 2024
Sleep Quality and Its Influence on Chronic Kidney DiseaseApril 29, 2024
Medulance is Official Emergency Services Partner of Delhi Capitals for a second time in IPL 2024April 29, 2024
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal VaccineApril 29, 2024
Moving Towards Better Mental Health: Know The Impact of Low-intensity Workout For Your Mental Well-being April 29, 2024
Exploring Mortality Risks for Lesbian and Bisexual Women: Key Findings from a Comprehensive Research EffortApril 29, 2024
Implications of Alcohol Intake During Pregnancy on Fetal Development: New Study Reveals Subtle ChangesApril 29, 2024
Indian Air Force's Night Vision Rescue: Soldier’s Life Saved in High-Stakes AirliftApril 29, 2024
Now You Can Also Buy Insurance For Your Parents Aged Above 65 years: IRDAI Lifts Age Cap for Health Insurance Expanding Healthcare AccessApril 29, 2024
Ensuring Infection Control: Central Government Hospitals Implement New Safety MeasuresApril 29, 2024
9th Edition of the India Health and Wellness Awards 2024 Celebrate Excellence in Healthcare, Innovations in Health and Patient Centric Approach RecognisedApril 27, 2024
Dish TV Revolutionizes Entertainment with ‘Dish TV Smart+’ Services, Offering TV and OTT on Any Screen, AnywhereApril 26, 2024
Arohan Financial Services Recognized Among India's Best Workplaces in BFSI 2024April 26, 2024
Why Podcasts Are the Next Big Thing in Healthcare Advertising in IndiaApril 26, 2024
Challenges of Child Growth at High Altitudes: New Study Reveals ImpactApril 26, 2024
Staying Cool in India's Scorching Heat: Heatwave Safety TipsApril 26, 2024
The Dark Side of Neotame (Artificial Sweetener): New Research Raises Concerns about Gut HealthApril 26, 2024
Sightsavers India Fellowship Program Invites Applications for Promising OphthalmologistsApril 25, 2024